SYROS PHARMACEUTICALS INC (SYRS)
US87184Q2066 - Common Stock
Taking everything into account, SYRS scores 2 out of 10 in our fundamental rating. SYRS was compared to 565 industry peers in the Biotechnology industry. SYRS has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, SYRS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year SYRS has reported negative net income.
In the past year SYRS has reported a negative cash flow from operations.
In the past 5 years SYRS always reported negative net income.
SYRS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
SYRS has a worse Return On Assets (-115.08%) than 79.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -115.08% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-61.3%
ROA(5y)-54.72%
ROE(3y)-387.81%
ROE(5y)-270.29%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SYRS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SYRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SYRS has more shares outstanding
SYRS has more shares outstanding than it did 5 years ago.
SYRS has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -16.24, we must say that SYRS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -16.24, SYRS is not doing good in the industry: 83.96% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.24 |
ROIC/WACCN/A
WACC9.83%
2.3 Liquidity
A Current Ratio of 2.25 indicates that SYRS has no problem at all paying its short term obligations.
SYRS has a Current ratio of 2.25. This is in the lower half of the industry: SYRS underperforms 73.97% of its industry peers.
SYRS has a Quick Ratio of 2.25. This indicates that SYRS is financially healthy and has no problem in meeting its short term obligations.
SYRS has a Quick ratio of 2.25. This is in the lower half of the industry: SYRS underperforms 72.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.25 | ||
| Quick Ratio | 2.25 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 19.20% over the past year.
Looking at the last year, SYRS shows a very negative growth in Revenue. The Revenue has decreased by -95.61% in the last year.
SYRS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.12% yearly.
EPS 1Y (TTM)19.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.81%
Revenue 1Y (TTM)-95.61%
Revenue growth 3Y-13%
Revenue growth 5Y37.12%
Sales Q2Q%-100%
3.2 Future
Based on estimates for the next years, SYRS will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.64% on average per year.
Based on estimates for the next years, SYRS will show a very strong growth in Revenue. The Revenue will grow by 115.59% on average per year.
EPS Next Y72.13%
EPS Next 2Y23.68%
EPS Next 3Y18.95%
EPS Next 5Y17.64%
Revenue Next Year-96.87%
Revenue Next 2Y-41.07%
Revenue Next 3Y51.81%
Revenue Next 5Y115.59%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SYRS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SYRS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SYRS's earnings are expected to grow with 18.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.68%
EPS Next 3Y18.95%
5. Dividend
5.1 Amount
No dividends for SYRS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SYROS PHARMACEUTICALS INC
NASDAQ:SYRS (11/15/2024, 8:00:00 PM)
After market: 0.2566 0 (-1.04%)0.2593
-0.02 (-5.74%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap6.96M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -115.08% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.25 | ||
| Quick Ratio | 2.25 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)19.2%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y72.13%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-95.61%
Revenue growth 3Y-13%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y